6 Jun 2026
ZERO Biotech, a clinical-stage radiopharmaceutical company and Hong Kong's only full-licensed central radiopharmacy for therapeutic radiopharmaceuticals, took center stage at the “Mix & Mingle: The Cancer MedTech Translational Hub” event hosted by Hong Kong Science and Technology Parks Corporation (HKSTP) on 5th June 2026 at the Hong Kong Science Park .
Mr. Clement Tam, CEO of ZERO Biotech, delivered a compelling presentation titled “Radiopharmaceuticals for Future Cancer Care,” sharing insights into the company's pioneering work in advancing targeted radio nuclear cancer diagnostics and therapies.
The event served as a vibrant platform for knowledge exchange and partnership-building, connecting innovators, clinicians, investors, and industry leaders driving breakthroughs in oncology. ZERO Biotech's participation underscores the company's commitment to positioning Hong Kong as a key player in the rapidly evolving nuclear medicine landscape.
A Leader in Hong Kong's Nuclear Medicine Sector
Since its founding in 2015, ZERO Biotech has taken an unconventional yet highly effective path. ZERO adopted a "smart positioning" strategy—building a revenue-generating manufacturing backbone while simultaneously pushing upstream into novel R&D.
Operating Hong Kong’s only full-licensed central radiopharmacy for therapeutic agents, the company operates with clockwork precision. Every day, scientific staff begin compounding life-saving radiopharmaceuticals as early as 5:00 AM, ensuring that major hospitals across the city receive their critical doses before 9:00 AM. To date, the company has successfully compounded over 160 therapeutic radiopharmaceutical injections for patients battling neuroendocrine tumors (NETs) and other aggressive cancers.
A Night of Connection, Collaboration, and Catalyst
The “Mix & Mingle” event was far more than a networking reception—it was a testament to Hong Kong’s growing stature as a translational MedTech hub. The evening buzzed with energy as pioneers from diverse disciplines exchanged ideas, forged partnerships, and envisioned a future where the "bench-to-bedside" journey is shorter, smarter, and more impactful.
“Events like these are the catalysts we need to accelerate innovation. The connections made here tonight will shape the next wave of cancer care,” said Clement Tam. “We are incredibly proud to be part of this vibrant Cancer MedTech community in Hong Kong, and we are just getting started.”
As ZERO Biotech continues to scale its operations, deepen its clinical pipeline, and expand its global partnerships, one thing is clear: the company is not just participating in the future of oncology—it is actively building it, one isotope at a time.
